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Abstract
Introduction: Nocardial infections, although rare, are challenging for clinicians to treat. Recent contradictory reports
of sulfonamide resistance have raised concerns about using this drug to treat nocardial infections.
Case presentation: A 62-year-old immunocompetent Caucasian woman showed disseminated pulmonary nodules
and a brain abscess by chest computed tomography and brain magnetic resonance imaging, respectively.
Multidrug-resistant Nocardia wallacei was cultured from a stereotactic brain biopsy and confirmed by 16S ribosomal
ribonucleic acid gene sequencing. After the first-line treatment failed, a long course of trimethoprim-sulfamethoxazole
was prescribed with no evidence of recurrence. To the best of our knowledge, this is the first report of a Nocardia
wallacei disseminated infection in an immunocompetent patient, and it is the first detailed description of successful
treatment with trimethoprim-sulfamethoxazole despite the resistance observed in vitro.
Conclusion: Species identification of clinical isolates is critical for diagnosis, a prediction of antimicrobial susceptibility
and epidemiological tracking. In the case of Nocardia wallacei, the clinical outcome suggests that sulfonamides can
be used for treatment despite ambiguous results from in vitro susceptibility tests.
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Introduction
Nocardia species are aerobic, Gram-positive bacteria of
the order Actinomycetales. They are ubiquitous in the
environment and live in soil, organic matter and wa-
ter. They have been recognized as opportunistic human
pathogens, and infection with Nocardia species usually
occurs through inhalation or direct cutaneous inocula-
tion. Recently, an increased number of nocardial infec-
tions, including brain abscess, have been reported in
individuals without significant immunosuppression [1].
To date, more than 50 Nocardia species have been
isolated from clinical infections, and our knowledge of
new species and taxonomic relationships is constantly
expanding [2]. Pijper and Pullinger reported the first
instance of a N. transvalensis infection in 1927 after iden-
tifying it as the causative agent of a mycetoma of the foot
in a South African patient [3]. In 1997, Wilson et al.
found that the drug pattern type IV of N. asteroides was
more closely related to N. transvalensis than to other
members of the N. asteroides complex, according to their
biochemical characteristics, molecular differences and
antimicrobial susceptibilities [4]. In 2008, Conville et al.
proposed that N. asteroides drug pattern IV be given the
new species designation of N. wallacei [5]. To the best of
our knowledge, our present report is the first case of dis-
seminated infection caused by N. wallacei in an immuno-
competent patient.
Recent sulfonamide susceptibility tests of N. wallacei
isolates in different laboratories gave contradictory results,
even when they were performed in duplicate [6]. This
variability raises questions regarding the accurate inter-
pretation of these susceptibility tests in clinical settings.
On the one hand, there have been recent alarming reports
of increased in vitro sulfonamide resistance in Nocardia
species [7-9], but on the other hand, the sulfonamide
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antibiotic combination of trimethoprim-sulfamethoxazole
(TMP-SMX) remains one of the first-choice drugs for
treating nocardiosis [1]. In this case report, we present
a patient who was successfully treated for a disseminated
infection caused by N. wallacei with a long course of
TMP-SMX after a first-line antibiotic therapy failure. Ini-
tial antibiotic susceptibility tests showed that the infecting
organism was resistant to multiple drugs, including sul-
fonamides. To the best of our knowledge, this is the first
case report that clearly describes the successful treatment
of a disseminated infection caused by N. wallacei with
sulfonamides despite an initial in vitro resistance.
Case presentation
A 62-year-old Caucasian woman living in an urban area
of Corsica was admitted to our hospital with an increas-
ing headache, breathing failure and pleuritic chest pain
on her right side. She had no relevant past medical his-
tory other than pneumonia 6 months ago. Because of
the persistence of dyspnea and radiographic findings
consistent with a recurrence of infection, she underwent
a fibroscopic bronchoalveolar lavage 1 month before ad-
mission. The culture grew Nocardia species, and the
susceptibility test results were pending at the time of ad-
mission. At admission, the patient was receiving a treat-
ment of ceftriaxone (1g) and amikacin (900mg) once a
day intravenously for 15 days. Her temperature was
38.2°C with 89% oxygen saturation in ambient air. Her
physical and neurological examinations were unremark-
able. Laboratory analyses yielded the following numbers:
hemoglobin concentration, 11.8g/dL; a white blood cell
count of 4 cells× 109/L (79% neutrophils, 8% lympho-
cytes); creatinine concentration, 0.68mg/dL and moder-
ately elevated C-reactive protein (62mg/L; normal is less
than 10mg/L). Blood cultures and a human immuno-
deficiency virus test were all negative. Chest computed
tomography (CT) revealed an interstitial distribution of
multiple pulmonary nodules, fluid in the major fissure
and a small pleural effusion. CT and magnetic reson-
ance imaging (MRI) brain scans conducted upon arrival
showed three nodular lesions in the left frontoparietal
lobe surrounded by perilesional edema with a faint ring
enhancement after contrast injection. The hyper-intense
appearance of the lesions in diffusion-weighted images of
the MRI scan was highly suggestive of a brain abscess.
Stereotactic brain biopsy of the lesions identified a modi-
fied acid-fast variable branching filamentous bacterium
that had morphology consistent with Nocardia species.
The final Nocardia species culture was obtained by inocu-
lating a Columbia agar plate containing 5% sheep blood
(bioMérieux) with pus from the abscess. The culture was
incubated at 37°C in a 5% carbon dioxide atmosphere.
The definite identification was based on the partial se-
quencing of the 16S ribosomal ribonucleic acid gene (over
a length of 1439 nucleotides) as previously described [10].
The sequencing results showed a 100% sequence similar-
ity with the N. wallacei reference sequence (GenBank ac-
cession number GQ853074.1). No other organisms were
isolated from the patient sample. The antibiotic suscepti-
bility of the isolate was assessed on Mueller-Hinton agar
(bioMérieux) using the disk method (Mast Diagnostics).
The isolate was determined to be susceptible to ceftriax-
one, ciprofloxacin and linezolid and resistant to amikacin,
co-trimoxazole and imipenem. These results were consist-
ent with susceptibility testing performed at the hospital of
origin using the disk method. According to the recom-
mendations of the Clinical and Laboratory Standards
Institute for the susceptibility testing of Nocardia spe-
cies, an additional antimicrobial test was performed by
the microdilution method, and this test indicated that the
isolate was susceptible to co-trimoxazole (minimum in-
hibitory concentration (MIC)<2/38mg/L) [11]. After ad-
mission, the patient received treatment with imipenem
(1g/8 hours) and amikacin (900mg/24 hours) and was
switched to linezolid (600mg/12 hours) and ciprofloxacin
(500mg/8 hours) after receiving the susceptibility test
results. Two weeks later, because of the appearance of
neurological signs such as Broca’s aphasia and the exten-
sion of the cerebral abscess while on treatment, a new
surgical drainage was performed by open craniotomy ex-
cision. The antibiotic regimen was switched to TMP-
SMX (2400mg/day-480mg/day) and linezolid (600mg/12
hours). The linezolid was stopped after a total of 4 weeks
to limit the risk of hematological toxicity. The neuro-
logical signs were improved, and the biological parame-
ters were normalized after 1 month of treatment. Six
months later, the patient presented with an isolated neu-
tropenia and concomitant skin rash consistent with a
hematological toxicity of the TMP-SMX. The treatment
was then switched to moxifloxacin (400mg/24 hours,
administered orally) for the remaining 6 months of the
treatment period. A 1-year followup after the antibi-
otic regimen ceased showed no evidence of a recurrent
infection.
Discussion
Although Nocardia species are a rare cause of intracranial
abscess and represent only 1% to 2% of all cerebral ab-
scesses, its mortality rate (31%) is considerably greater
than that of other agents that can cause cerebral abscesses
(<10%) [12]. In this context, an accurate diagnosis and
early treatment are challenging. Initial combination ther-
apy with two active agents is recommended for patients
with disseminated or severe nocardiosis [1]. Empirical
therapy should consider the local ecology (e.g., particular
strains, trends in antimicrobial susceptibility) and be
adapted after the antibiotic susceptibility testing. However,
these susceptibility tests may not always be reliable, as
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shown by the contradictory results of TMP-SMX sus-
ceptibility trends. Uhde et al. reported that among 765
Nocardia isolates submitted to the American Center
for Disease Control and Prevention in Atlanta, Georgia
from 1995 to 2004, 61% were resistant to SMX, and
42% were resistant to TMP-SMX [7]. In a 2011 study of
186 Nocardia species isolated from patients in Spain,
Larruskain et al. reported that 16.1% were resistant to
TMP-SMX [8]. A recent report from Canada stated that
43% of the 157 of Nocardia isolates recovered from
Quebec (1988 to 2008) were resistant to TMP-SMX [9].
By contrast, other researchers have reported a low inci-
dence of resistance to TMP-SMX. Brown-Elliot et al.
stated that among 552 susceptibility results submitted
for review, only 14 isolates (2.5%) were identified as
sulfonamide-resistant, with three isolates resistant to
TMP-SMX and 11 resistant to SMX [13]. These results
are strikingly similar to the low incidence (2%) of sul-
fonamide resistance observed by Lai et al. in a study of
Nocardia isolates in Taiwan [14]. The disparity among
the reported data, even in the same country, is of inter-
est because it suggests that factors other than geographic
location may play a major role in the susceptibility pat-
terns reported; the most probable factor is a difference in
methodology or interpretation. The exchange of organ-
isms between two or more accredited laboratories has
been proposed as a way to enhance the accuracy of sus-
ceptibility testing [13]. Despite this recommendation, a
recent multisite study by Conville et al. found that there
was a lack of reproducibility for the sulfonamide MIC re-
sults, especially when testing N. wallacei and even within
a particular reference laboratory [6]. Among the reasons
for this variability discussed by the authors was the diffi-
culty associated with obtaining a homogeneous organism
suspension or inoculum because of the clumping ability
of Nocardia species. Of interest, this study indicated that
the disk diffusion test for sulfonamides was useful for val-
idating the MIC results obtained by broth microdilution.
In our case, the results of these two susceptibility tests
were contradictory for sulfonamides.
N. wallacei is expected to be susceptible to TMP-SMX
and resistant to amikacin [6]. Isolates reported to be re-
sistant to sulfonamides have nonetheless been successfully
treated with sulfonamides [9]. However, rare clinical re-
ports have described the treatment failure of Nocardia
with TMP-SMX [15]. In the present case, the clinical re-
sponse to TMP-SMX was discordant with the results of
the initial in vitro susceptibility test. Recently, large micro-
biological studies have raised concerns regarding the
limits of interpretation of the TMX-SMX susceptibility
test results. This is the first case of disseminated infection
caused by N. wallacei that demonstrates the conflict be-
tween the in vitro resistance to sulfonamides and the clin-
ical response to TMP-SMX.
Conclusion
We consider it necessary to preserve the traditional
approach to empirical therapy for infections involving
Nocardia species, and this therapy almost always includes
TMP-SMX. One must consider the inherent difficulties of
interpreting MIC results when evaluating reports of re-
sistance to TMP-SMX. In the present case, the clinical
outcome and species identification guided the treatment
irrespective of the results of the susceptibility test.
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